EGFR L858R is a predictive biomarker for use of afatinib, erlotinib, gefitinib, osimertinib, capmatinib, crizotinib, dacomitinib, cetuximab, and pembrolizumab in patients. Of the …

Aug 15, 2023 · In summary, our study identified L858R as a potential predictive biomarker and uncovered a clear advantage of cetuximab over TKIs in terms of preventing relapses of L858R …

Aug 15, 2023 · These results identify L858R as a predictive biomarker, which may pave the way for relapse-free mAb monotherapy relevant to a large fraction of patients with lung cancer.

May 10, 2018 · We used CRISPR/Cas9 system to target a commonly occurring EGFR point mutation, L858R, with an oligonucleotide guide that recognizes L858R as the suitable …

Aug 8, 2023 · We report that osimertinib’s inferiority associates with induction of mutagenic reactive oxygen species, whereas cetuximab’s superiority is due to downregulation of adaptive …

Exon 19 deletion (ex19del) and exon 21 L858R (ex21 L858R) mutations account for ~45 and 40% of all EGFR mutations, respectively. Moreover, EGFR-tyrosine kinase inhibitors (TKIs) may be …

Aug 26, 2022 · Patients with EGFR L858R mutation treated with anti-angiogenic therapy in their course of treatment had a significantly prolonged OS compared to those who had never …

May 31, 2023 · Conclusions: L858R have distinct co-mutations and copy number alterations compared to ex19del, in addition to a higher representation of smoking mutational signature …

Mar 11, 2025 · The L858R mutation reshapes cell proliferation by altering how lung cancer cells progress through the cell cycle. Normally, division is regulated by growth factor availability, …

Sep 4, 2015 · Recent studies indicate that the frequency of the L858R mutant form of the epidermal growth factor receptor (EGFR-L858R) is higher in lung adenocarcinoma with MPE …

Nov 18, 2017 · In this double-blind, phase 3 trial, we randomly assigned 556 patients with previously untreated, EGFR mutation–positive (exon 19 deletion or L858R) advanced NSCLC …

WHAT ARE THE BIOLOGICAL DIFFERENCES BETWEEN EXON 19 DEL AND EXON 21 (L858R) AND HOW DO THEY DIFFERENTIALLY AFFECT TREATMENT OUTCOMES? The …

Sep 19, 2020 · Epidermal growth factor receptor (EGFR) mutations such as exon 19 deletions (Ex19del) and exon 21 codon p.Leu858Arg (L858R) point mutations are common oncogenic …

Aug 15, 2023 · In summary, our study identified L858R as a potential predictive biomarker and uncovered a clear advantage of cetuximab over TKIs in terms of preventing relapses of L858R …

Sep 4, 2015 · Our findings demonstrate that lung adenocarcinomas harboring the EGFR-L858R mutation exhibit increased cancer cell invasive ability and MPE formation through activation of …

Oct 1, 2022 · Based on the extendable blocking probes and hot-start protocol for reverse transcription, we have developed and validated a novel one-step realtime RT-PCR assay that …

L858R mutation is a single nucleotide variant in exon 21 in the tyrosine kinase domain of the EGFR gene. This missense mutation located at the coding position 2573, causing nucleotide …

Jan 10, 2018 · Genetic analysis is now routine in metastatic non–small-cell lung cancer (NSCLC) to identify somatic sensitizing mutations in EGFR, typically L858R and exon 19 deletion …

EGFR tyrosine kinase inhibitors (TKIs) are generally indicated in this type of lung cancer. We report a case of lung adenocarcinoma with EGFR L858R mutation caused by a rare 2-base …

Sep 6, 2023 · The most common EGFR mutations are EGFR 19 deletion or EGFR L858R point mutation. Rarer mutations, such as EGFR exon 20 insertions, have different treatments …

Mar 25, 2025 · TAGRISSO is indicated in combination with pemetrexed and platinum-based chemotherapy, for the first-line treatment of adult patients with locally advanced or metastatic …